BAY-1436032 is an inhibitor of the mutant IDH1 enzyme, which is being studied and developed for use in cancer treatment, particularly for cancers with IDH1 gene mutations, such as Acute Myeloid Leukemia (AML) and glioma brain cancer. This compound works by inhibiting the production of 2-hydroxyglutarate (2-HG) resulting from IDH1 mutations, a substance that promotes cancer cell growth. The use of BAY-1436032 helps to slow or stop the growth of cancer cells and may induce cancer cells to return to a normal state. Additionally, research is ongoing to evaluate its efficacy and safety in treating other cancers associated with IDH1 mutations.